Kolexia
Dieras Veronique Oncologie médicale
Dieras Veronique
Oncologie médicale
Clcc Institut Curie
Paris, France
473 Activités
249 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Tumeurs du cerveau Récidive tumorale locale Cellules tumorales circulantes Carcinomes Tumeur du sein de l'homme Effets secondaires indésirables des médicaments

Collaborateurs

Voir plus
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Campone Mario
Campone Mario
Ico - Site Paul Papin, Angers, France
Goncalves Anthony
Goncalves Anthony
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Daiichi Sankyo
51 collaboration(s)
Dernière en 2023
Pfizer
37 collaboration(s)
Dernière en 2023
Seagen
28 collaboration(s)
Dernière en 2023
Gilead
25 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   29 février 2024
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Essai Clinique (Abbvie)   19 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Molecular oncology   29 janvier 2024
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.
European journal of cancer (Oxford, England : 1990)   28 janvier 2024
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
Essai Clinique (Alliance Foundation Trials, LLC.)   22 janvier 2024
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   22 janvier 2024
AMBRE: Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease
Essai Clinique (Unicancer)   19 janvier 2024
DAISY: Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy
Essai Clinique (Daiichi Sankyo)   06 décembre 2023